

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5799902

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
SEQUENCE:	2	
CONVEYING PARTY DATA		
	Name	Execution Date
	JANSSEN PHARMACEUTICA NV	07/19/2019
RECEIVING PARTY DATA		
Name:	JANSSEN SCIENCES IRELAND UNLIMITED COMPANY	
Street Address:	BARNAHELY	
City:	RINGASKIDDY, CO CORK	
State/Country:	IRELAND	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16352754
CORRESPONDENCE DATA		
Fax Number:	(857)300-4001	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	857-300-4003	
Email:	bostonpatent@lathropgage.com,dvincent@lathropgage.com,dpstein@lathropgage.com	
Correspondent Name:	BRIAN C. TRINQUE	
Address Line 1:	LATHROP & GAGE LLP	
Address Line 2:	28 STATE STREET	
Address Line 4:	BOSTON, MASSACHUSETTS 02109	
ATTORNEY DOCKET NUMBER:	611144: NTT-044	
NAME OF SUBMITTER:	BRIAN C. TRINQUE, PH.D., ESQ.	
SIGNATURE:	/BRIAN C. TRINQUE/	
DATE SIGNED:	11/01/2019	
Total Attachments: 2		
source=611144-NTT-044-1A-EXECUTED-ASSIGNMENT-JANSSEN-PHARMA-NV-TO-JANSSEN-SCIENCES-UNLIMITED		
source=611144-NTT-044-1A-EXECUTED-ASSIGNMENT-JANSSEN-PHARMA-NV-TO-JANSSEN-SCIENCES-UNLIMITED		

General Assignment

WHEREAS, Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, 2340, Beerse, Belgium (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

CAPSID ASSEMBLY MODULATOR DOSING REGIMEN

for which on March 13, 2019, US Patent Application no. 16/352,754 was filed at the United States Patent and Trademark Office.

WHEREAS, Janssen Sciences Ireland Unlimited Company, having its place of business at Barnahely Ringaskiddy, Co Cork, Ireland (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,


NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the March 13, 2019.

IN TESTIMONY WHEREOF, the Assignor set hereunto its hand and seal this date.

FOR Janssen Pharmaceutica NV



Signature


Luc Quaghebeur
Name

Authorized Signatory of Janssen Pharmaceutica NV
Title of Authorized Signatory

Date: *19 July* 2019

IN TESTIMONY WHEREOF, the Assignee set hereunto its hand and seal this date.

FOR Janssen Sciences Ireland Unlimited Company



Signature

Frank Daelemans
Name

Authorized Signatory of Janssen Sciences Ireland Unlimited Company
Title of Authorized Signatory

Date: *23 July* 2019